

## Advantagene names Glenn Mattes SVP and Chief Operating Officer

**Auburndale, MA, June 15, 2016 - Advantagene, Inc.**, a clinical-stage biotechnology company developing a novel cancer immunotherapy platform for the treatment of solid tumors, announced today that Glenn Mattes has been named Senior Vice President and Chief Operating Officer, effective immediately. As SVP and COO, Mr. Mattes will be primarily responsible for the design and implementation of operational strategies to ensure timely and efficient achievement of corporate goals. Mr. Mattes will remain a member of the company's board of directors.

Mr. Mattes brings over thirty years of successful leadership experience in the pharmaceutical industry. He has effectively led major operating divisions at global pharmaceutical companies, had primary product launch and commercialization responsibilities and has significant emerging company management, financing and partnering expertise. He is currently Executive Chairman of Translational Sciences, Inc. (*Memphis, TN*). In this role he actively works with senior management to determine and implement strategic priorities. In September, 2015, the company consummated a global strategic collaboration with Daiichi Sankyo and Mr. Mattes is a member of the Translational Sciences/Daiichi Sankyo collaboration Joint Steering Committee. Prior to joining Translational Sciences, he was CEO of Arno Therapeutics (*Flemington, NJ*), a publicly traded company with a portfolio of development stage oncology therapeutic compounds where he successfully guided the company through a number of financing transactions to sufficiently capitalize the company.

From 2002 to 2011, Mr. Mattes served as President, Tibotec Therapeutics (*Titusville, NJ*), a Johnson & Johnson operating company, where he led the organization responsible for the development, marketing and sales of oncology and novel antiretroviral therapeutics in North America. Under Mr. Mattes' leadership, the sales and market position of an oncology portfolio that included *Doxil* and *Procrit* (partnered with Ortho Biotech) grew significantly with *Procrit* becoming the market leader for treatment of anemia associated with chemotherapy. During his tenure at Tibotec, Mr. Mattes also led the successful launch of the first two Johnson & Johnson products in the United States HIV/AIDS market. Previously, from 1998 to 2002, Mr. Mattes served as Vice President of Worldwide Commercial Operations at Centocor (*Malvern, PA*), where he played a critical role in defining Centocor's overall business direction as well as developing and implementing the organization's strategy leading to the commercial launch of *Remicade*. Prior to joining Centocor, Mr. Mattes was at Rhone Poulenc Rorer (*Collegeville, PA*) where he held positions of increasing responsibility, including President of RPR Canada and General Manager of Advanced Therapeutics and Oncology, North America, where he was responsible for the successful launch of oncology blockbusters *Taxotere* and *Lovenox*.

In 2008, Mr. Mattes was appointed to the President's Advisory Council on HIV/AIDS (PACHA) by the U.S. Secretary of Health and Human Services. In this role, he was a key contributor to the committee that had the responsibility to counsel both the Bush and Obama administrations on domestic and global health and treatment issues. Mr. Mattes is also currently an adviser to The Gores Group (*Los Angeles, CA*) and PTV Healthcare (*Austin, TX*), private equity healthcare firms, the Clayton Foundation (*Houston, Texas*), a not-for-profit developing vaccines, and a number of private development stage life science companies including Cornovus Pharmaceuticals (*Farmington, CT*). Mr. Mattes received a BS degree from the City University of New York.

## **About Advantagene, Inc.**

Advantagene is a Massachusetts based biotechnology company developing its proprietary Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform technology for the treatment of solid tumors. GMCI™ is an “off the shelf” low toxicity immunotherapy that stimulates a patient’s own immune system to generate a robust response against his or her individual cancer. Advantagene is conducting a registration clinical trial with its lead candidate, ProstAtak®, under a Special Protocol Assessment approved by the U.S. Food and Drug Administration, for the treatment of localized prostate cancer patients with intermediate to high risk disease choosing radiation therapy. If proven efficacious, ProstAtak® will be the first and only therapeutic pharmaceutical available for newly diagnosed localized prostate cancer patients. The company is conducting additional GMCI clinical studies in lung, pancreas and brain cancers with remarkable clinical results to date. For more information about Advantagene and our GMCI™ cancer immunotherapy program please visit [www.advantagene.com](http://www.advantagene.com).

### Contact

#### *Media & Investor Relations*

Advantagene, Inc.  
440 Lexington Avenue  
Auburndale, MA 02466  
(617) 916-5445  
info@advantagene.com

Released June 15, 2016